Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation.
BACKGROUND
Weight gain is commonly observed during psychotropic treatments for chronic forms of severe mental illness and is most rapid during the early treatment phases. All formats of behavioural weight intervention programmes have suggested that weight gain can be prevented or reversed in some patients. There is no data on these programmes in acutely unwell inpatients whom may be the major beneficiaries.


METHODS
A modular behavioural intervention programme (Solutions for Wellness) used in SMI outpatients since 2002 in Ireland has been adapted for inpatient use. Preliminary data is reported from 5 centres in Ireland.


RESULTS
In 47 inpatients the mean weight change was +0.26 kg (SD 2.02) with a median change of 0 kg. Mean follow-up was 23.7 (SD 21.6) days, and median 14 days (range 6-98 days). There was no difference in mean weight change in those patients involved for > 35 days compared with < 35 days (+0.26 kg; 0.25 kg; p = 0.5). Weight loss or maintenance was seen in 70% of patients.


CONCLUSIONS
These preliminary data are supportive of the concept that acutely unwell inpatients with SMI may engage with a behavioural weight programme. Weight change observed contrasts with the significant weight gain often seen in most subjects. Further clinical trials are warranted.
Bushe
Chris J
CJ
Eli Lilly and Company Ltd, Adelaide Road, Dublin, Ireland. bushe_chris@lilly.com
McNamara
Dermot
D
Haley
Cliff
C
McCrossan
Mary Fleming
MF
Devitt
Pat
P
D000208:Acute Disease; D000328:Adult; D001521:Behavior Therapy / Q000379:methods*; D001835:Body Weight; D015331:Cohort Studies; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007494:Ireland / Q000453:epidemiology; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology / Q000534:rehabilitation*; D015397:Program Evaluation; D012720:Severity of Illness Index
Aust N Z J Psychiatry. 2005 Jun;39(6):479-86
15943650
J Clin Psychiatry. 2005 Feb;66(2):205-12
15705006
Arch Gen Psychiatry. 2007 Feb;64(2):242-9
17283292
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005148
17253540
Am Heart J. 2005 Dec;150(6):1115-21
16338246
Psychiatr Serv. 2003 Aug;54(8):1155-7
12883145
J Clin Psychiatry. 2008 Apr;69(4):555-62
18312061
J Clin Psychiatry. 2004 Apr;65(4):471-7
15119908
Acta Psychiatr Scand. 2007 Apr;115(4):286-94
17355519
Hum Psychopharmacol. 2005 Aug;20(6):447-8
16106486
J Psychopharmacol. 2005 Nov;19(6 Suppl):16-27
16280334
Pharmacopsychiatry. 2008 Jan;41(1):17-23
18203047
Am J Psychiatry. 2007 Jul;164(7):1050-60
17606657
Int J Obes Relat Metab Disord. 2002 Jan;26(1):137-41
11791159
Eur Psychiatry. 2007 Oct;22(7):413-8
17765483
Br J Psychiatry. 2003 Jan;182:31-6
12509315
Acta Psychiatr Scand. 2006 Jul;114(1):49-54
16774661
J Psychopharmacol. 2005 Nov;19(6 Suppl):28-35
16280335
Acta Psychiatr Scand. 2005 Mar;111(3):232-43
15701108
Schizophr Res. 2005 Dec 1;80(1):19-32
16137860
J Clin Psychiatry. 2005 Dec;66(12):1576-9
16401160
Eur Neuropsychopharmacol. 2007 Mar;17(4):235-44
17137759
Int Clin Psychopharmacol. 2002 Jul;17(4):145-60
12131598
Acta Psychiatr Scand. 2003 Oct;108(4):252-9
12956825